Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Formula E and Google Cloud have recently announced a new multi-year AI and technology partnership which kicked off with the groundbreaking GEN3 Evo era.

Google has rolled out major updates to its Gemini AI models, enhancing their speed, intelligence, and accessibility for ...

The leaders spoke on the day the body of one of the three men who went missing in Mlolongo, was found at City Mortuary in Nairobi. Justus Musyimi was found dead in Ruai and the body was moved to ...

Wall St ends lower as White House says Trump to implement tariffs February 1, 2025 The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...

--Up 15.27% month-to-date; on pace for best month since May 2024, when it rose 15.92% --Up 15.27% year-to-date --Down 10.17% from its all-time closing high of $516.74 on Nov. 8, 2024 --Up 9.3% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...